Fight the big belly with valsartan. Can antihypertensive medications affect the related parameters with obesity?

Dorota Zozulińska-Ziółkiewicz

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

5/2017
vol. 3

Send email

Copy url:

abstract:

Review paper

Fight the big belly with valsartan. Can antihypertensive medications affect the related parameters with obesity?

Dorota Zozulińska-Ziółkiewicz

Online publish date: 2017/11/29

View full text Get citation

Abdominal obesity is a manifestation of severe metabolic disturbances with the common background that is insulin resistance. Hypertension often accompanies obesity. When choosing antihypertensive drugs in obese patients physicians should take into account its impact on metabolism. Activation of the abdominal obesity-induced renin–angiotensin–aldosterone system justifies the preference of antihypertensive drugs blocking this system, i.e. converting enzyme inhibitors and angiotensin receptor blockers. Based on inference analysis of clinical trials and the results of experimental studies, the slogan Fight the big belly with valsartan becomes understandable.

keywords:

Fight the big belly with valsartan. Can antihypertensive medications affect the related parameters with obesity?

Dorota Zozulińska-Ziółkiewicz

abdominal obesity, hypertension, renin–angiotensin–aldosterone system, valsartan